Table 2 Pathways significantly enriched in the top cancer proteins ranked by network properties
From: A comparative study of cancer proteins in the human protein-protein interaction network
Ranking | KEGG entry | Pathway name | No. of genea | P valueb | FDR P valuec |
|---|---|---|---|---|---|
1 | hsa05215 | Prostate cancer | 15 | 1.8 × 10 –19 | 4.5 × 10–18 |
2 | hsa05220 | Chronic myeloid leukemia | 12 | 1.3 × 10 –15 | 1.6 × 10–14 |
3 | hsa05219 | Bladder cancer | 9 | 1.3 × 10 –13 | 1.1 × 10–12 |
4 | hsa05213 | Endometrial cancer | 9 | 1.3 × 10 –12 | 8.4 × 10–12 |
5 | hsa05223 | Non-small cell lung cancer | 8 | 8.2 × 10–11 | 4.1 × 10–10 |
6 | hsa05210 | Colorectal cancer | 9 | 2.0 × 10–10 | 8.4 × 10–10 |
7 | hsa05214 | Glioma | 8 | 4.6 × 10–10 | 1.7 × 10–9 |
8 | hsa05216 | Thyroid cancer | 6 | 8.1 × 10–10 | 2.5 × 10–9 |
9 | hsa05218 | Melanoma | 8 | 1.0 × 10–9 | 2.9 × 10–9 |
10 | hsa05212 | Pancreatic cancer | 8 | 1.2 × 10–9 | 3.0 × 10–9 |
11 | hsa05221 | Acute myeloid leukemia | 7 | 4.4 × 10–9 | 1.0 × 10–8 |
12 | hsa04012 | ErbB signaling pathway | 8 | 6.7 × 10–9 | 1.4 × 10–8 |
13 | hsa05211 | Renal cell carcinoma | 7 | 2.1 × 10–8 | 4.0 × 10–8 |
14 | hsa04110 | Cell cycle | 8 | 1.1 × 10–7 | 1.9 × 10–7 |
15 | hsa05222 | Small cell lung cancer | 7 | 1.2 × 10–7 | 2.0 × 10–7 |
16 | hsa04630 | Jak-STAT signaling pathway | 8 | 1.0 × 10–6 | 1.6 × 10–6 |
17 | hsa04520 | Adherens junction | 6 | 1.1 × 10–6 | 1.6 × 10–6 |
18 | hsa04916 | Melanogenesis | 6 | 6.6 × 10–6 | 9.1 × 10–6 |
19 | hsa04310 | Wnt signaling pathway | 7 | 9.6 × 10–6 | 1.3 × 10–5 |
20 | hsa04660 | T cell receptor signaling pathway | 5 | 4.9 × 10–5 | 6.2 × 10–5 |
21 | hsa04510 | Focal adhesion | 7 | 7.8 × 10–5 | 9.3 × 10–5 |
22 | hsa04650 | Natural killer cell mediated cytotoxicity | 5 | 3.7 × 10–4 | 4.2 × 10–4 |
23 | hsa04120 | Ubiquitin mediated proteolysis | 5 | 4.0 × 10–4 | 4.3 × 10–4 |
24 | hsa04010 | MAPK signaling pathway | 7 | 5.6 × 10–4 | 5.9 × 10–4 |